MX344197B - Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides. - Google Patents

Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.

Info

Publication number
MX344197B
MX344197B MX2013004889A MX2013004889A MX344197B MX 344197 B MX344197 B MX 344197B MX 2013004889 A MX2013004889 A MX 2013004889A MX 2013004889 A MX2013004889 A MX 2013004889A MX 344197 B MX344197 B MX 344197B
Authority
MX
Mexico
Prior art keywords
glucocorticoids
glucocorticoid
relates
component
designed
Prior art date
Application number
MX2013004889A
Other languages
English (en)
Spanish (es)
Inventor
Hedner Thomas
Skrtic Stanko
Johnsson Jörgen
Lennernäs Hans
Johannsson Gudmundur
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of MX344197B publication Critical patent/MX344197B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MX2013004889A 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides. MX344197B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
MX344197B true MX344197B (es) 2016-12-08

Family

ID=35197481

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004889A MX344197B (es) 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.
MXPA06012011A MXPA06012011A (es) 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA06012011A MXPA06012011A (es) 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.

Country Status (25)

Country Link
US (3) US8425937B2 (https=)
EP (2) EP3072507B1 (https=)
JP (2) JP5149618B2 (https=)
CN (2) CN1942176B (https=)
AU (1) AU2005235370B2 (https=)
BR (1) BRPI0510044B8 (https=)
CA (1) CA2564000C (https=)
CY (2) CY1118275T1 (https=)
DK (2) DK1744730T3 (https=)
ES (2) ES2857600T3 (https=)
HR (2) HRP20161380T1 (https=)
HU (2) HUE053248T2 (https=)
IL (2) IL178776A (https=)
LT (2) LT3072507T (https=)
ME (1) ME02584B (https=)
MX (2) MX344197B (https=)
NZ (1) NZ585340A (https=)
PL (2) PL1744730T3 (https=)
PT (2) PT1744730T (https=)
RS (2) RS55198B1 (https=)
SE (1) SE0401031D0 (https=)
SG (1) SG188081A1 (https=)
SI (1) SI3072507T1 (https=)
WO (1) WO2005102271A2 (https=)
ZA (1) ZA200609680B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007533697A (ja) 2004-04-22 2007-11-22 デュオコート エービー グルココルチコイド救急治療用の医薬組成物
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
EP1971312A1 (en) * 2005-12-06 2008-09-24 MonoSol Rx LLC Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
ES2358158T3 (es) * 2008-07-21 2011-05-06 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento del tracto digestivo superior.
NZ595428A (en) * 2009-04-07 2013-04-26 Duocourt Pharma Ab Improved glucocorticoid therapy
PE20131024A1 (es) 2010-05-20 2013-10-10 Duocort Pharma Ab Composiciones basadas en glucocorticoides
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
DK2986280T3 (da) * 2013-04-16 2021-06-14 Murray & Poole Entpr Ltd Formuleringer med langvarig frigivelse af colchicin og fremgangsmåder til brug af samme
CA2909370A1 (en) * 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
PT2886108T (pt) 2013-12-23 2019-04-01 Dr Falk Pharma Gmbh Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
WO2026052804A1 (en) 2024-09-06 2026-03-12 Institut National de la Santé et de la Recherche Médicale Hydrocortisone based oral dispersible film and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
ATE253899T1 (de) 1994-01-31 2003-11-15 Yamanouchi Pharma Co Ltd Intraoral löslicher formpressling und verfahren zu seiner herstellung
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
AP1748A (en) * 2001-03-13 2007-06-11 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
AU2002254205B2 (en) * 2001-03-15 2007-05-10 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003066029A2 (en) 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
JP2007533697A (ja) 2004-04-22 2007-11-22 デュオコート エービー グルココルチコイド救急治療用の医薬組成物
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
NZ595428A (en) 2009-04-07 2013-04-26 Duocourt Pharma Ab Improved glucocorticoid therapy
PE20131024A1 (es) 2010-05-20 2013-10-10 Duocort Pharma Ab Composiciones basadas en glucocorticoides

Also Published As

Publication number Publication date
CY1124074T1 (el) 2022-03-24
CN103006592A (zh) 2013-04-03
MXPA06012011A (es) 2007-04-16
SI3072507T1 (sl) 2021-04-30
DK1744730T3 (en) 2016-08-29
DK3072507T3 (da) 2021-02-08
WO2005102271A2 (en) 2005-11-03
IL178776A (en) 2013-10-31
US20080187586A1 (en) 2008-08-07
RS61501B1 (sr) 2021-03-31
HRP20210348T1 (hr) 2021-04-16
HUE053248T2 (hu) 2021-06-28
HK1179525A1 (zh) 2013-10-04
CA2564000C (en) 2013-07-02
US20130129823A1 (en) 2013-05-23
JP2012236846A (ja) 2012-12-06
NZ585340A (en) 2012-04-27
EP3072507A1 (en) 2016-09-28
PL1744730T3 (pl) 2017-01-31
CN1942176B (zh) 2013-09-18
IL227375A (en) 2017-08-31
PL3072507T3 (pl) 2021-07-19
CN103006592B (zh) 2016-03-02
US20140242167A1 (en) 2014-08-28
AU2005235370B2 (en) 2011-06-09
JP5681679B2 (ja) 2015-03-11
PT1744730T (pt) 2016-10-07
EP1744730B1 (en) 2016-08-03
AU2005235370A1 (en) 2005-11-03
JP2007533698A (ja) 2007-11-22
CY1118275T1 (el) 2017-06-28
LT3072507T (lt) 2021-02-25
ES2600556T3 (es) 2017-02-09
JP5149618B2 (ja) 2013-02-20
BRPI0510044A (pt) 2007-10-16
EP3072507B1 (en) 2020-12-23
EP1744730A2 (en) 2007-01-24
BRPI0510044B1 (pt) 2019-01-29
CA2564000A1 (en) 2005-11-03
ME02584B (me) 2017-06-20
HRP20161380T1 (hr) 2016-12-02
WO2005102271A3 (en) 2006-08-03
US8425937B2 (en) 2013-04-23
PT3072507T (pt) 2021-02-23
ZA200609680B (en) 2008-08-27
US10583146B2 (en) 2020-03-10
BRPI0510044B8 (pt) 2021-05-25
HUE030546T2 (en) 2017-05-29
CN1942176A (zh) 2007-04-04
RS55198B1 (sr) 2017-01-31
SG188081A1 (en) 2013-03-28
SE0401031D0 (sv) 2004-04-22
IL178776A0 (en) 2007-02-11
LT1744730T (lt) 2016-10-25
ES2857600T3 (es) 2021-09-29

Similar Documents

Publication Publication Date Title
MX344197B (es) Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
WO2005039505A3 (en) Compositions and methods for healthy pregnancy
MY176679A (en) Use of nutritional compositions for preventing disorders
MY151018A (en) Use of nutritional compositions for preventing disorders
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
EP2628486A3 (en) Method for treating bone fracture with anti-sclerostin antibodies
de Campos et al. Smoking modulates gene expression of type I collagen, bone sialoprotein, and osteocalcin in human alveolar bone
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
EP1651161A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR ACCELERATING WOUND HEALING
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
TW200509937A (en) Novel compounds and their use in therapy
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
Rodrigues et al. Long-term dose-and time-dependent effects of endodontic sealers in human in vitro osteoclastogenesis
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
Srisawasdi et al. Different Roles of Dexamethasone on Transforming Growth Factor-β1–induced Fibronectin and Nerve Growth Factor Expression in Dental Pulp Cells
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
Faccioni et al. Short‐term “in vivo” study on cellular DNA damage induced by acrylic Andresen activator in oral mucosa cells
WO2006093858A3 (en) Method and composition for treating diabetes
WO2006102979A3 (de) Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen
WO2005028504A3 (en) Regulation of tissue mineralization and phosphate met abolism by asarm peptides
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten